LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
1,82 щ.д.
0,00%
(0,00) 1 д.
1,81 щ.д.
arrow_downward
-0,68% (-0,012)bedtimeСлед затварянето на борсата
Затворено: 2.10, 16:00:01 ч. Гринуич-4 · USD
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за LXRX…
Отваряне
1,85 щ.д.
Висока
1,87 щ.д.
Ниска
1,80 щ.д.
Пазарна кап.
809,82 млн.
Ср. обем
3,13 млн.
Обем
2,32 млн.
Най-висока цена за 52 седм.
2,68 щ.д.
Най-ниска цена за 52 седм.
1,10 щ.д.
EPS
-0,15 щ.д.
Бета-версия
1,36
Акции в обращение
444,96 млн.
Брой служители
81
Отваряне
1,85 щ.д.
Висока
1,87 щ.д.
Ниска
1,80 щ.д.
Пазарна кап.
809,82 млн.
Ср. обем
3,13 млн.
Обем
2,32 млн.
Най-висока цена за 52 седм.
2,68 щ.д.
Най-ниска цена за 52 седм.
1,10 щ.д.
EPS
-0,15 щ.д.
Бета-версия
1,36
Акции в обращение
444,96 млн.
Брой служители
81
Новинарски материали
От източници в мрежата и новинарски партньори
AD HOC NEWS
·
преди 1 ден
Cantor Fitzgerald targets Lexicon Pharmaceuticals stock at USD 8.00
Seeking Alpha
·
преди 2 дни
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Профил
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
Всичко за Lexicon Pharmaceuticals Inc
Главен изпълнителен директорЛонел Коутс
Служители81
Дата на основаване1995
Централен офис-
Бранш-
Уебсайтlexpharma.com